Skip to Main Content

Shareholder Class Action Filed Against Chiasma, Inc.

View Complaint

Notice is hereby given that a class action lawsuit has been filed on behalf of those who purchased or otherwise acquired shares of Chiasma, Inc. (“Chiasma”) (NASDAQ: CHMA): (1) pursuant and/or traceable to Chiasma’s Registration Statement and Prospectus issued in connection with the Company’s initial public offering on or about July 15, 2015 (the “IPO” or the “Offering”); and/or (2) on the open market between July 15, 2015 and April 17, 2016, both dates inclusive.

Chiasma investors may receive additional information about the case by clicking the link "Join this Class Action" above.  


According to the complaint, a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases.  The company’s lead product candidate is oral octreotide, or Mycapssa, for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

The complaint alleges that the defendants made materially false and misleading statements regarding the company’s business, operational and compliance policies. Specifically, the complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that: (i) Chiasma’s Phase 3 clinical trial methodology for Mycapssa was not sufficient to demonstrate efficacy and secure FDA approval; (ii) Chiasma’s supervision of its suppliers was not sufficient to prevent deficiencies that would delay FDA approval of Mycapssa; and (iii) as a result of the foregoing, Chiasma’s public statements were materially false and misleading at all relevant times.

On or about July 15, 2016, Chiasma completed its IPO, issuing 6.4 million shares and raising net proceeds of approximately $102 million.

According to the complaint, on April 18, 2016, before the market opened, the company announced that the FDA had issued a Complete Response Letter regarding its New Drug Application for Mycapssa. In a press release, Chiasma stated, in part, “the FDA advised Chiasma that the Agency did not believe the company’s application had provided substantial evidence of efficacy to warrant approval, and advised Chiasma that it would need to conduct another clinical trial in order to overcome this deficiency.”

Following this news, Chiasma’s share price fell $6.42, or 63.13%, to close at $3.75 on April 18, 2016.

If you are a member of the class described above, you may no later than August 8, 2016 move the Court to serve as lead plaintiff of the class, if you so choose. 

 A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of their choice, or may choose to do nothing and remain an inactive class member.

Kessler Topaz Meltzer & Check, LLP has not filed a complaint in this matter.  If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at For more information about Kessler Topaz Meltzer & Check, LLP, please visit our website at

Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087 1-888-299-7706 (toll free) or 1-610-667-7706
Or by e-mail at

Please complete this form and list your purchase and sale transaction(s) for Chiasma, Inc.  (NASDAQ: CHMA)pursuant and/or traceable to Chiasma’s Registration Statement and Prospectus issued in connection with the Company’s initial public offering on or about July 15, 2015:

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Chiasma, Inc. prior to the Class Period?
Are you a current or former employee of Chiasma, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email